KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics.

Amanda J Guise, Kyle L Ferber, Damon Young, Amanda L Edwards, Somayeh Sabouri, Kyle B Fraser, Eric Milliman, Edward D Plowey, Jad Zoghbi, Stephanie M Fradette, Danielle L Graham

Cell Rep Med 7(3) 102648

PMID41850233
PMCIDPMC13006395
DOI10.1016/j.xcrm.2026.102648
发表日期2026-03-18
入排依据:The study is a randomized Phase III trial of a drug intervention with original results, but it investigates amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, not a human malignant neoplasm (cancer). Therefore, it is excluded from the oncology Kaplan-Meier cohort.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 1:非 KM 图;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。
摘要

摘要

Tofersen, the first approved genetically targeted therapy for amyotrophic lateral sclerosis (ALS), demonstrates significant lowering of plasma neurofilament in adults carrying mutations in the superoxide dismutase 1 (SOD1) gene; however, additional biomarkers of treatment response in ALS are lacking. Here, we analyze longitudinally collected cerebrospinal fluid (CSF) samples from the phase 3 VALOR clinical trial to identify candidate tofersen treatment-response biomarkers in SOD1-ALS via quantitative proteomics. We observe significant modulation from baseline abundance for 56 proteins in tofersen-treated participants relative to placebo, including CSF GPNMB, which is significantly and continuously elevated across all post-baseline timepoints. We orthogonally confirm this observation by GPNMB immunoassay in independent tofersen-treated cohorts. Taken together, these data identify pharmacodynamic-response biomarkers of tofersen treatment that can be measured as early as 4 weeks post-treatment in SOD1-ALS patients and demonstrate the utility of leveraging unbiased proteomic screening integrated with targeted validation methods to identify pharmacodynamic-response biomarkers in clinical trial patient samples.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1Exploratory biomarker discovery via quantitative proteomic screening of longitudinal SOD1-ALS CSF samples (A) Study workflow: (1) longitudinal CSF samples were collected from tofersen- or placebo-treated individuals enrolled in VALOR; (2) extracted proteins were digested and labeled with isobaric peptide tags (TMT) and combined into sets with a 2:1 (ASO:PBO) donor ratio. TMT sets were (3) fractionated and sequenced (MS2) and quantified (MS3) by mass spectrometry. Resulting spectra were searched against a reviewed human protein database, and (4) linear statistical models were generated to identify candidate biomarkers. (B) Total proteins quantitated applying a global 1% FDR per 16-plex TMT set. Red bars indicate sets with low protein identifications that were excluded from downstream analyses. (C) Distribution of frequency of quantitation for individual protein species across TMT sets. Proteins quantified in >50% of sets were included in downstream analyses. (D) PCA plots for each time point of tofersen-treated (green) and placebo-treated samples (blue) based on 405 proteins quantified across all sets with no missing values. Asterisks (∗) indicate baseline outliers that were excluded from further analyses. Indeed, one of these two apparent outliers (N-127N) corresponded to a sample for which no starting material was available, but which was included as a placeholder and internal control. Based on its similarity in behavior to the empty N-127N sample, we also excluded N-130C from downstream analyses, even though peptides were detected for this sample.
非 KM Figure
Figure 2Identification of PD-response biomarkers based on abundance change from baseline (A) Change from baseline in SOD1 protein abundance over 16 weeks in placebo-treated (blue) or tofersen-treated (green) SOD1 -ALS donors. Ratio to baseline = 1 indicates no change. (B and C) Volcano plot of differentially abundant proteins in CSF from tofersen-treated relative to placebo-treated donors at (B) 4 and (C) 16 weeks following treatment initiation. Effect sizes are shown as log 2 -transformed geometric mean ratios (log 2 GMR). Significantly differentially abundant PD-response biomarker candidates ( p adj < 0.1) are shown in color; SOD1 protein is highlighted in red. (D) Significantly overrepresented gene ontology (GO) terms associated with week 16 PD-response biomarker candidates determined via hypergeometric test relative to the background CSF proteome.
非 KM Figure
Figure 3Increased abundance of CSF immunoglobulins is consistent with elevation of CSF white blood cell counts in tofersen-treated individuals (A) Change from baseline in CSF abundance of immunoglobulins IGHM (left) and IGJ (right) over 16 weeks in placebo-treated (blue) or tofersen-treated (green) SOD1 -ALS donors. Ratio to baseline = 1 indicates no change. (B) Spearman correlation scores for change in protein abundance for PD-response candidates vs. change in CSF white blood cell counts (WBCCs) at each time point up to 16 weeks for IGHM, IGJ, and EMIL2. (C) Correlation plots for change in IGHM (upper) and IGJ (lower) CSF abundance vs. CSF WBCCs over time for tofersen-treated (green) and placebo-treated (blue) populations.
非 KM Figure
Figure 4CSF GPNMB is a validated biomarker of tofersen PD response (A) Change from baseline in CSF abundance of GPNMB over 16 weeks in placebo-treated (blue) or tofersen-treated (green) SOD1 -ALS subjects enrolled in VALOR Part C as measured by multiplexed mass spectrometry (TMT). Ratio to baseline = 1 indicates no change. (B) Change from baseline in CSF abundance of GPNMB over 16 weeks in placebo-treated (blue) or tofersen-treated (green) SOD1 -ALS subjects enrolled in VALOR Part C as measured by quantitative immunoassay (ELISA). Ratio to baseline = 1 indicates no change. (C) Correlation plots of log 2 -transformed TMT-based vs. ELISA-based CSF GPNMB abundance measures in placebo- (blue) or tofersen-treated (green) groups at individual timepoints. Sample sizes indicate number of participants per group; ELISA measures were collected in at least duplicate for each subject, and all data points are plotted. (D) Treatment effect (placebo-adjusted change from baseline) on CSF GPNMB over 24 weeks for SOD1 -ALS subjects enrolled in VALOR Part B belonging to either the 60 mg tofersen (gray) or 100 mg tofersen (green) dose groups as measured by ELISA. Ratio to baseline = 1 indicates no change (red dashed line). Error bars indicate 95% confidence intervals. (E) Correlation between baseline CSF GPMNB and plasma NfL concentration, both measured by immunoassay. (F) Association of changes from baseline in CSF GPNMB and changes from baseline in plasma NfL in placebo (black), tofersen (green), or pooled treatment (black) at all post-baseline time points (weeks 4–16).
非 KM Figure